CDK4 and breast cancer: This consistency between studies further suggests the relatively robust utility of intrinsic subtyping of the BL subtype as resistant to CDK4/6 inhibitors and could be considered in future biomarker trial design when evaluating the efficacy of CDK4/6 inhibitors alone or in combination with other experimental drugs in an early breast cancer setting.